Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56911—Bacteria
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6854—Immunoglobulins
  • G01N33/6857—Antibody fragments
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
  • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2469/00—Immunoassays for the detection of microorganisms
  • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• Tick-Borne Relapsing Fever TBRF
• B. borgdorferi the B. borgdorferi group and the Tick-Borne Relapsing Fever (TBRF) Borrelia group. It was believed that the B.
• borgdorferi group was the only group that caused Lyme-like symptoms in infected subjects. However, it has been learned that TBRF Borrelia also causes Lyme-like symptoms. TBRF Borrelia is transmitted by hard (Ixodes) and soft (Ornithodorus) ticks.
• Borrelia bacteria that cause TBRF are typically transmitted to humans through the bite of infected“soft ticks” of the genus Ornithodorus.
• Soft ticks differ in two important ways from the more familiar“hard ticks” (e.g., the dog tick and the deer tick).
• the bite of soft ticks is brief, usually lasting less than half an hour.
• soft ticks do not search for prey in tall grass or brush. Instead, they live within rodent burrows, feeding as needed on the rodent (for example, squirrels, chipmunks and prairie dogs) as it sleeps.
• TBRF TBRF fever
• high fever e.g., 103° F
• headache e.g., headache
• muscle and joint aches e.g., headache
• Symptoms can reoccur, producing a telltale pattern of fever lasting roughly 3 days, followed by 7 days without fever, followed by another 3 days of fever. Without antibiotic treatment, this process can repeat several times.
• ticks may return to the nesting materials in their host burrows.
• B. hermsii is transmitted by O. hermsi ticks, B. parkerii by O. parkeri ticks, and B. turicatae by O. turicata ticks.
• Each tick species has a preferred habitat and preferred set of hosts.
• Soft ticks can live up to 10 years. Individual ticks will take many blood meals during each stage of their life cycle, and some species can pass the infection along through their eggs to their offspring. The long life span of soft ticks means that once a cabin or homestead is infested, it may remain infested unless steps are taken to find and remove the rodent nest.
• identification of the Borrelia species can aid in identifying the host rodent for eradication.
• the standard for identification is by identification of TBRF spirochetes in blood smears of a subject presenting symptoms consistent with TBRF. After obtaining the blood draw the sample must be cultured for at least 24 hours to facilitate identification. However, even early in the disease when spirochetes are highest, positive identification is only made about 70% of the time. (See, www.cdc.gov/relapsing-fever/clinicians/index.html). Thus, prior art materials and methods result in a delay in diagnosis and provide a relatively low level of sensitivity and specificity.
• the present invention solves these problems in the prior art by providing antigen- specific amino acid sequences for TBRF Borrelia specific species. These novel amino acid sequences are used in assays to identify TBRF specific Borrelia in samples from subjects suspected of having TBRF. With the amino acid sequences of the present invention, identification of TBRF Borrelia in subject samples is performed with greater speed, sensitivity and specificity than the prior art methods.
• the amino acid sequences of the present invention can be used in diagnostic and scientific assays. Examples of suitable assays are Immunoblots, ELISA (enzyme-linked immunosorbent assay), etc.
• amino acid sequences of the present invention can be used for the detection of TBRF Borrelia specific T-cells ⁇ e.g., the IgXSPOT test; IGeneX, Palo Alto, CA). Further, and importantly, antigens encoded by the amino acid sequences of the present invention can be used in vaccination protocols.
• the present invention contemplates a composition comprising one or more labeled and/or tagged and/or bound amino acid sequences, said amino acid sequences consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
• SEQ ID NO: 6 SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20.
• the present invention further contemplates that the sequences of the present invention, when bound, are bound to a substance selected from the group consisting of nitrocellulose, nylon, polyvinylidene difluoride (PVDF), magnetic beads and agarose.
• a substance selected from the group consisting of nitrocellulose, nylon, polyvinylidene difluoride (PVDF), magnetic beads and agarose.
• the present invention further contemplates that the sequences of the present invention, when tagged, are tagged with an antibody with specificity for said amino acid sequence.
• the present invention contemplates a method of detecting Borrelia
• TBRF tick-borne relapsing fever
• the present invention further contemplates that two or more of the labeled and/or tagged and/or bound amino acid sequences of the present invention are mixed with the biological sample.
• a sample is considered positive for TBRF if at least two amino acid sequences are detected.
• a sample is considered positive for TBRF if at least one amino acid sequences is detected.
• the present invention further contemplates that the labeled and/or tagged and/or bound amino acid sequences are detected with anti-human IgG antibody linked to a detectable moiety.
• the detectable moiety may be selected from the group consisting of chromophores, radioactive moieties and enzymes.
• the present invention contemplates that the detectable moiety may comprise alkaline phosphatase.
• the present invention contemplates that the detectable moiety may comprise biotin.
• the present invention further contemplates a method of detecting and
• TBRF tick-borne relapsing fever
• detection of SEQ ID NO: 3, SEQ ID NO: 8, SEQ D NO: 12 and/or SEQ ID NO: 14 indicates the presence of B. miyamotoi in the subject
• SEQ ID NO: 9 and/or SEQ ID NO: 15 indicates the presence of B. turcica in the subject
• detection of SEQ ID NO: 6 and/or SEQ ID NO: 10 indicates the detection of B. turicatae in the sample
• detection of SEQ ID NO: 18, SEQ ID NO: 19 and/or SEQ ID NO: 20 indicates the detection of B. coriaceae in the sample.
• the labeled and/or tagged and/or bound amino acid sequences may be detected with anti-human IgG antibody conjugated to a detectable moiety.
• the present invention further contemplates that the labeled and/or tagged and/or bound amino acid sequences are detected with anti-human IgG antibody linked to a detectable moiety.
• the detectable moiety may be selected from the group consisting of chromophores, radioactive moieties and enzymes.
• the present invention contemplates that the detectable moiety may comprise alkaline phosphatase.
• the present invention contemplates that the detectable moiety may comprise biotin.
• the present invention further contemplates that a sample is considered positive for Borrelia if at least one amino acid sequence is detected.
• the present invention further contemplates that a sample is considered positive for a specific species of Borrelia if at least one amino acid sequence identified with a specific species is detected.
• the present invention contemplates a method of detecting B. hermsii in a sample from a subject suspected of having tick-borne relapsing fever (TBRF), said method comprising: providing a biological sample obtained from a subject suspected of having TBRF, mixing the biological sample with one or more of the labeled and/or tagged and/or bound amino acid sequences selected from the group of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 16 and/or SEQ ID NO: 17 of Clam 1 and detecting a positive immunobinding reaction of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 16 and/or SEQ ID NO: 17 the detection
• the present invention contemplates a method of detecting B. miyamotoi in a sample from a subject suspected of having tick-borne relapsing fever (TBRF), said method comprising: providing a biological sample obtained from a subject suspected of having TBRF, mixing the biological sample with one or more of the labeled and/or bound amino acid sequences selected from the group of SEQ ID NO: 3, SEQ ID NO: 8, SEQ D NO: 12 and/or SEQ ID NO: 14 of Clam 1 and detecting a positive immunobinding reaction of SEQ ID NO: 3, SEQ ID NO: 8, SEQ D NO: 12 and/or SEQ ID NO: 14 which indicates the presence of B. miyamotoi in the sample
• the present invention contemplates a method of detecting B. turcica in a sample from a subject suspected of having tick-borne relapsing fever (TBRF), said method comprising: providing a biological sample obtained from a subject suspected of having TBRF, mixing the biological sample with one or more of the labeled and/or tagged and/or bound amino acid sequences selected from the group of SEQ ID NO: 4, SEQ ID NO: 5; SEQ ID NO: 9 and/or SEQ ID NO: 15 of Clam 1 and detecting a positive immunobinding reaction of SEQ ID NO: 4, SEQ ID NO: 5; SEQ ID NO: 9 and/or SEQ ID NO: 15 which indicates the presence of B. turcica in the sample.
• TBRF tick-borne relapsing fever
• the present invention contemplates a method of detecting B. turicatae in a
• sample from a subject suspected of having tick-borne relapsing fever comprising: providing a biological sample obtained from a subject suspected of having TBRF, mixing the biological sample with one or more of the labeled and/or tagged and/or bound amino acid sequences selected from the group of SEQ ID NO: 6 and/or SEQ ID NO: 10 of Clam 1 and detecting a positive immunobinding reaction of SEQ ID NO: 6 and/or SEQ ID NO: 10 which indicates the presence of B. turicatae in the sample.
• the present invention contemplates a method of detecting B. coriaceae in a sample from a subject suspected of having tick-borne relapsing fever (TBRF), said method comprising: providing a biological sample obtained from a subject suspected of having TBRF, mixing the biological sample with one or more of the labeled and/or tagged and/or bound amino acid sequences selected from the group of SEQ ID NO: 18, SEQ ID NO: 19 and/or SEQ ID NO: 20 of Clam 1 and detecting a positive
• the present invention further contemplates a composition
• a composition comprising, consisting essentially of or consisting of one or more amino acid sequences selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, and an adjuvant.
• the present invention further contemplates a nucleic acid sequence encoding any one or more of the amino acid sequences of the present invention. Said nucleic acid sequence may be labeled.
• the present invention further contemplates a method of detecting T cells from a subject having or suspected of having tick-borne relapsing fever (TBRF), the method comprising: providing i) a sample comprising T cells obtained from a subject suspected of having TBRF, ii) a culture apparatus coated at least partially with anti-antibodies specific for one or more cytokines and iii) one or more sequences of Claim 1 ; mixing the blood sample with the one or more of the sequences of Clam 1 in the culture apparatus, and detecting any production of the one or more cytokines by the subject’s T cells.
• the anti-antibodies that are specific for a cytokine are anti-IFNy antibodies and the cytokine is interferon gamma (IFNy).
• Figure 1 shows an Immunoblot using the TBRF Borrelia specific antigenic
• the present invention provides novel compositions and methods for diagnosing, treating and vaccinating against infection by Tick-Borne Relapsing Fever causing Borrelia sp.
• the invention is based, in part, on the discovery of species-specific amino acid sequences encoding antigenic peptides (which may also be referred to as peptide antigens or antigens in the art), as described below.
• the present invention provides nucleic acid sequences encoding the amino acid sequences of the present invention. The nucleic acid sequences may be labeled.
• the present invention provides for antigenic amino acid sequences specific for various Borrelia species.
• the amino acid sequences of the present invention encode antigenic peptides that have high specificity and/or sensitivity for the indicated species.
• the present invention in one aspect, is a composition comprising one or more labeled and/or bound amino acid sequences, said amino acid sequences having 90%, 95%, 98%, 99%, 99.5% and/or 100% homology to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20.
• Sequences less than 100% homologous may have deletions, additions and or substitutions of the 100% homologous sequence.
• One of ordinary skill in the art can easily determine if sequences less than 100% homologous can bind naturally or non-naturally occurring TBRF-related antibodies as well as the sensitivity and specificity of the antibody to the modified sequences.
• sequences with significant homology to SEQ ID NOs: 1 - 20 of the present invention that give acceptable or equivalent responses in the methods of the present invention without undue experimentation, in view of the teachings of this specification.
• the present invention in one aspect, is a composition comprising one or more labeled and/or tagged and/or bound amino acid sequences, said amino acid sequences consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
• SEQ ID NO: 6 SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20.
• the phrase“a composition comprising one or more labeled and/or tagged and/or bound amino acid sequences, said amino acid sequences consisting of,” encompasses a composition having the one or more of the recited sequences and, for example, buffers, labels, etc. In other words, the sequence is limited to the sequence or sequences given but the composition is not limited.
• the definition specifically excludes amino acids naturally contiguous with a recited sequence being used as a label or tag as an element of the“composition comprising.”
• a“tagged” amino acid sequence is an amino acid sequence that is attached to a detectable moiety.
• Non-limiting examples of such“tags” are natural and synthetic (i.e., non-naturally occurring) nucleic acid and amino acid sequences (e.g., poly-AAA tags), antibodies and detectable moieties such as labels (discussed below).
• the definitions of the phrases“labeled” and“tagged” may have overlap in that a tag may also, in some instances, function as a label.
• tags useful with the present invention may be linked to a label.
• amino acid sequences of the present invention may be labeled with any suitable label known to one of ordinary skill in the art.
• suitable labels may include, but are not limited to, biotin/streptavidin, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase (AP), glucose oxidase and b-galactosidase), fluorescent moieties (e.g., FITC, fluorescein, rhodamine, etc.), biological fluorophores (e.g., green fluorescent protein, R-phycoerythrin) or other luminescent proteins, etc.
• HRP horseradish peroxidase
• AP alkaline phosphatase
• b-galactosidase e.g., glucose oxidase and b-galactosidase
• fluorescent moieties e.g., FITC, fluorescein, rhodamine, etc.
• the amino acid sequences of the present invention may be“bound.”
• a “bound” amino acid sequence is an amino acid sequence that has been immobilized in order to permit the use of the amino acid sequence in a biological test such as, for example, immunoassays.
• a“bound” amino acid sequence is an amino acid sequence attached (e.g., covalently or non-covalently bound, etc.) directly or indirectly to a non-natural surface or substance.
• the“bound” amino acid sequences of the present invention may be attached, directly or indirectly, to a natural surface or substance, either of which is not naturally associated with the amino acid sequence.
• Non-limiting examples of substances to which the amino acid sequences of the present invention may be bound are nitrocellulose, nylon,
• PVDF polyvinylidene difluoride
• plastics plastics
• metals metals
• magnetic beads e.g., beads
• agarose e.g., beads
• the present invention in one aspect, is a composition comprising, consisting essentially of or consisting of one or more labeled and/or tagged and/or bound amino acid sequences, said amino acid sequences consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO:
• amino acid sequences of the present invention may be natural occurring and isolated from a natural source. Further, the amino acid sequences of the present invention may be non-natural, synthetic sequences, such as sequences produced by recombinant technology or sequences synthesized by protein synthesizing apparatuses. As such, the amino acid sequences of the present invention may be isolated or may be produced by recombinant technology, as is described and enabled in the literature and in commonly referred to manuals such as, e.g., Short Protocols in Molecular Biology, Second Edition, F.M. Ausubel, Ed., all John Wiley & Sons, N.Y., edition as of 2008; and, Sambrook, et al.
• amino acid sequences of the present invention are made recombinantly in E. coli.
• amino acid sequences of the present invention may be tagged with an
• antibody with specificity for any of said amino acid sequences is the property of antibodies which enables them to react preferentially with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces and molecular structure at the binding site. Sensitivity is how strongly the antibody binds to the antigenic determinant.
• affinity assays such as immunoblotting, Ouchterlony assays, titer assays, etc.
• the present invention provides a method of quickly and
• TBRF tick-borne relapsing fever
• a subject suspected of having TBRF can be identified as having symptoms such as a high fever (e.g., 103° F), headache, muscle and joint aches. Symptoms typically reoccur, producing a telltale pattern of fever lasting roughly 3 days, followed by approximately 7 days without fever, followed by another 3 days of fever. Without proper antibiotic treatment, this process can repeat several times. Since the symptoms of TBRF can mimic, for example, viral flu-like symptoms, accurate diagnosis of TBRF is important for providing an effective treatment for the subject.
• the present invention provides a quick and easy diagnostic test for detecting the presence of antibodies specific for the causative Borrelia species, thereby satisfying the need for such a test.
• the method of the present invention for detecting Borrelia antisera in a sample from a subject suspected of having TBRF may comprise, for example, providing a biological sample (e.g., blood, saliva) obtained from a subject suspected of having TBRF, mixing the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention and detecting a positive reaction which indicates the presence of TBRF antisera in the sample.
• the antisera may be detected by, for example, immunoblotting, Elispot, ELISA, Western blotting or any other appropriate immunoassay known to one of ordinary skill in the art. These techniques are known to one of ordinary skill in the art and procedures can be found in common technical references. While similar, each of these techniques has its advantages and disadvantages. Other suitable techniques may be known to those of skill in the art and are incorporated herein.
• Western blotting can involve separating proteins by electrophoresis and then transferring to nitrocellulose or other solid media (e.g., polyvinylidene fluoride or PVDF-membrane and nylon membrane), and is described in more detail below.
• solid media e.g., polyvinylidene fluoride or PVDF-membrane and nylon membrane
• Immunoblotting can also involve applying proteins to a solid media manually or by machine.
• the proteins are applied in straight lines or spots and dried, binding them to the solid support medium, e.g., nitrocellulose.
• the proteins used in an immunoblot can be isolated from biological samples or produced by recombinant technology, as is well known by those of ordinary skill in the art. The bound proteins are then exposed to a sample or samples suspected of having antibodies specific for the target proteins.
• a known antibody can be used to determine if a protein is present in a sample, such as when the proteins of lysed cells are separated by electrophoresis and transferred to the solid medium.
• Western blotting allows for the identification of proteins by size as well as by specificity for a specific antibody.
• proteins can be bound to the solid medium and samples, such as samples from subjects suspected of having an infection, can be tested for the presence of specific antibodies in the sample by contacting the bound protein with the sample.
• An antibody that binds the target protein is usually referred to as the primary antibody.
• a secondary antibody, specific for conserved regions of the primary antibody (for example, a rabbit-anti-human IgG antibody may be used to detect primary human antibodies) is used to detect any bound primary antibodies.
• the secondary antibody is usually labeled with a detectable moiety for visualization.
• suitable labels include, for example, chromophores such as biotin, radioactive moieties and enzymes such as alkaline phosphatase, etc.
• the Enzyme-Linked ImmunoSpot (ELISPOT) method can detect human T cells that respond to TBRFspecific antigens in vitro.
• ELISPOT Enzyme-Linked ImmunoSpot
• the surfaces of PVDF membrane in a 96-well microtiter plate are coated with capture antibody that binds, for example, anti-lnterferon gamma (IFNy) or other cytokine-specific antibody.
• IFNy anti-lnterferon gamma
• the T cells isolated from patient whole blood are seeded into the wells of the plate along with aforementioned sequence(s), and form substantially a monolayer on the membrane surface of the well.
• any antigen-specific cells Upon stimulation of any antigen-specific cells with one or more of the sequences of the present invention they are activated and they release the IFNy, which is captured directly on the membrane surface by the immobilized antibody.
• the IFNy is thus“captured” in the area directly surrounding the secreting cell, before it has a chance to diffuse into the culture media, or to be degraded by proteases and bound by receptors on bystander cells. Subsequent detection steps visualize the immobilized IFNy as an ImmunoSpot;
• each well of the plate is coated with a purified cytokine-specific antibody specific for the test or cell being detected.
• Subject /.e., a subject suspected of having TBRF
• T cells are isolated and cultured in each well and stimulated with recombinant antigens of one or more sequences of the present invention.
• TBRF-positive patient cells secrete cytokine in response to stimuli, which is captured by the antibody coated in the well and further detected by ELISA.
• ELISA assays are also used to detect antigens.
• the ELISA assay can permit the quantification of a specific protein in a mix of proteins (for example, a lysate) or determine if a peptide is present in a sample.
• ELISA assays can be used to determine if a specific antibody is present by using a specific antigen as a target.
• target amino acid sequence(s) are attached to a surface. Then, if present in the sample being tested, the reactive antibody can bind to the antigen.
• a secondary antibody linked to an enzyme is added, and, in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate.
• a positive result is indicated when two or more of the labeled and/or bound amino acid sequences of the present invention are mixed with the biological sample and when at least two amino acid sequences are detected.
• a positive result is indicated when at least one of the labeled and/or bound amino acid sequences of the present invention are mixed with the biological sample and when at least one amino acid sequence is detected.
• any primary antibody bound to a peptide encoded by an amino acid sequence of the present invention may be detected with anti human antibodies, such as IgG or IgM, used as the secondary antibody conjugated to a detectable moiety.
• the detectable moiety may be selected from the group consisting of chromophores, radioactivity moieties and enzymes or other detectable moiety known to one of ordinary skill in the art.
• the detectable moiety comprises alkaline phosphatase.
• the detectable moiety comprises biotin.
• the sample may be from a subject suspected of having TBRF.
• the method may comprise, for example, providing a sample, for example, a biological sample obtained from a subject suspected of having TBRF and mixing or contacting the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention. Amino acids may be labeled to confirm their presence if positive results are not obtained in the assay.
• the detection of a positive immunobinding reaction indicates the presence of Borrelia in the sample, wherein detection of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 16 and/or SEQ ID NO: 17 indicates the presence of B. hermsii, in the sample; detection of SEQ ID NO: 3, SEQ ID NO: 8, SEQ D NO: 12 and/or SEQ ID NO: 14 indicates the presence of B. miyamotoi in the sample; detection of SEQ ID NO: 4, SEQ ID NO: 5; SEQ ID NO: 9 and/or SEQ ID NO: 15 indicates the presence of B.
• a sample is considered positive for Borrelia if at least two amino acid sequences are detected.
• a sample is considered positive for a specific species of Borrelia if at least two amino acid sequences identified with a species are detected.
• a sample is considered positive for Borrelia if at least one amino acid sequence is detected.
• a sample is considered positive for a specific species of Borrelia if at least one amino acid sequence identified with a species is detected.
• the sample may be from a subject suspected of having TBRF.
• the method may comprise, for example, providing a sample, for example, a biological sample obtained from a subject suspected of having TBRF and mixing or contacting the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention specific for B. hermsii.
• the detection of a positive immunobinding reaction of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 16 and/or SEQ ID NO: 17 indicates the presence of B. hermsii, in the sample.
• the assay used may be any of the assays described elsewhere in this specification, or as are known to one of ordinary skill in the art.
• a sample is considered positive for B. hermsii if at least one amino acid sequence is detected.
• the sample may be from a subject suspected of having TBRF.
• the method may comprise, for example, providing a sample, for example, a biological sample obtained from a subject suspected of having TBRF and mixing or contacting the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention.
• the detection of, for example, a positive immunobinding reaction of SEQ ID NO: 3, SEQ ID NO: 8, SEQ D NO: 12 and/or SEQ ID NO: 14 indicates the presence of B. miyamotoi in the sample.
• the assay used may be any of the assays described elsewhere in this specification, or as are known to one of ordinary skill in the art.
• a sample is considered positive for B. miyamotoi if at least one amino acid sequence is detected.
• a method is provided for detecting and distinguishing various species of B. turcica in a sample.
• the sample may be from a subject suspected of having TBRF.
• the method may comprise, for example, providing a sample, for example, a biological sample obtained from a subject suspected of having TBRF and mixing or contacting the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention.
• the detection of, for example, a positive immunobinding reaction of SEQ ID NO: 4, SEQ ID NO: 5; SEQ ID NO: 9 and/or SEQ ID NO: 15 indicates the presence of B. turcica in the sample.
• the assay used may be any of the assays described elsewhere in this specification, or as are known to one of ordinary skill in the art. A sample is considered positive for B.
• the sample may be from a subject suspected of having TBRF.
• the method may comprise, for example, providing a sample, for example, a biological sample obtained from a subject suspected of having TBRF and mixing or contacting the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention.
• the detection of, for example, a positive immunobinding reaction of SEQ ID NO: 6 and/or SEQ ID NO: 10 indicates the detection of B. turicatae in the sample.
• the assay used may be any of the assays described elsewhere in this specification, or as are known to one of ordinary skill in the art.
• a sample is considered positive for B. turicatae if at least one amino acid sequence is detected.
• the sample may be from a subject suspected of having TBRF.
• the method may comprise, for example, providing a sample, for example, a biological sample obtained from a subject suspected of having TBRF and mixing or contacting the biological sample with one or more of the labeled and/or bound amino acid sequences of the present invention.
• the detection of, for example, a positive immunobinding reaction of SEQ ID NO: 18, SEQ ID NO: 19 and/or SEQ ID NO: 20 indicates the detection of B. coriaceae in the sample.
• the assay used may be any of the assays described elsewhere in this specification, or as are known to one of ordinary skill in the art.
• a sample is considered positive for B. coriaceae if at least one amino acid sequence is detected.
• Vaccination protocols are well known to one of ordinary skill in the art. Briefly, vaccination is the administration of antigenic material (a vaccine) to stimulate an individual's immune system to develop adaptive immunity to a pathogen. Vaccines can prevent or ameliorate morbidity from infection.
• a vaccine antigenic material
• Vaccines are typically administered with adjuvants.
• Adjuvants are compounds and mixtures of compounds designed or found to aid in stimulation of the immune system.
• an adjuvant is a pharmacological or immunological agent that modifies the effect of other agents.
• Adjuvants may be added to a vaccine to modify the immune response by boosting it such as to produce a greater quantity of antibodies and provide longer-lasting protection, thus minimizing the amount of injected foreign material.
• Adjuvants may also be used to enhance the efficacy of a vaccine by helping to modify the immune response to particular types of immune system cells. There are different classes of adjuvants that can skew immune responses in different directions.
• adjuvants may selectively skew the immune response by preferentially activating T cells or B cells depending on the purpose of the vaccine.
• adjuvants may also be used in the production of antibodies from immunized animals.
• rabbit anti-human IgG antibodies may be produced by inoculating a rabbit with conserved portions of a human IgG antibody in combination with an adjuvant.
• the most commonly used adjuvants include aluminum hydroxide, paraffin oil and Freud’s complete and incomplete adjuvant.
• adjuvants such as alum
• Some adjuvants function as delivery systems by generating depots that trap antigens at the injection site, providing a slow release that continues to stimulate the immune system.
• Other adjuvants augment or stimulation the host immune response by providing a general boost to the immune system.
• another aspect of the present invention is a composition
• a composition comprising or consisting essentially of one or more amino acid sequences, said amino acid sequences having 90%, 95%, 98%, 99%, 99.5% and/or 100% homology selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 and an adjuvant.
• the adjuvant may be any adjuvant known to one of ordinary skill in the art suitable for use in humans. Combinations two or more adjuvants may be used. One of ordinary skill in the art will be able to identify sequences of the present invention that give acceptable or equivalent immunological responses without undue
• Isolated nucleic acid sequences including polynucleotides and oligonucleotides, encoding the amino acid sequences of the present invention, and portions thereof, may be expressed in cultured cells to provide isolatable quantities of peptides displaying biological (e.g., immunological) properties of the antigenic peptide encoded by the amino acid sequences of the present invention. Because of redundancy of the genetic code, multiple nucleic acid sequences may be suitable for the production of the peptide sequences of the present invention. One of ordinary skill in the art will be able to determine one or more nucleic acid sequences for the production of the amino acid sequences of the present invention.
• the nucleic acid sequences encoding the amino acid sequences of the present invention may be labeled by any suitable label known to one of ordinary skill in the art.
• nucleic acid sequences of suitable for the production of the amino acid sequences of the present invention may be substantially homologous to the naturally occurring sequences.
• Substantial homology of a nucleic acid sequence means either that (a) there is greater than about 65%, typically greater than about 75%, more typically greater than about 85%, preferably greater than about 95%, and more preferably greater than about 98% homology, most preferably 99% with the naturally occurring sequence or (b) the homologous nucleic acid sequence will hybridize to the compared sequence or its complementary strand under stringent conditions of the temperature and salt concentration.
• stringent conditions will generally be a temperature greater than about 22 °C, usually greater than about 30 °C and more usually greater than about 45 °C, and a salt concentration generally less than about 1 M, usually less than about 500 mM, and preferably less than about 200 mM.
• the combination of temperature and salt concentration is more important in defining stringency than either the temperature or the salt concentration alone.
• Other conditions which affect stringency include GC content of the compared sequence, extent of complementarity of the sequences, and length of the sequences involved in the hybridization, as well as the composition of buffer solution(s) used in the hybridization mixture. These and other factors affecting stringency are well described in the scientific and patent literature.
• One of ordinary skill in the art will be able to determine suitable conditions for determining the homology of the nucleic acid sequences encoding the antigenic peptides of the present invention.
• homologous nucleic acid sequences may be determined based on the nature of a nucleotide substitution in the nucleic acid sequence. For example, conservative nucleotide substitutions will be tolerated better and, therefore, can be more numerous in a particular nucleic acid sequence than non-conservative nucleotide substitutions.
• One or ordinary skill in the art will be able to determine the suitable number and location of substitutions that may be allowed in a nucleic acid sequence that encodes an amino acid sequence of the present invention without adversely affecting the species specificity of the encoded antigenic peptide, without undue experimentation.
• Borreliosis is caused by two groups of Borrelia, B. burgdorferi group and the
• Tick-Borne Relapsing Fever (TBRF) Borrelia group Tick-Borne Relapsing Fever (TBRF) Borrelia group. It was believed that B. burgdorferi group is the only group that causes Lyme-like symptoms. However it is now known that TBRF Borrelia can also cause Lyme-like symptoms. TBRF Borrelia can be transmitted by hard ( Ixodes ) and soft (Ornithodorus) ticks.
• the TBRF Borrelia immunoblot of the present invention is designed to detect antibodies to TBRF Borrelia species [including, but not limited to Borrelia miyamotoi, B. hermsii, B. turicatae and B. coriaceae] specific antigens in human serum.
• immunoblot test results may be used in conjunction with clinical symptoms and other evidence available to the diagnosing physician.
• the TBRF Borrelia ImmunoBlot Test is a qualitative immunoblot assay that detects antibodies directed against TBRF associated Borrelia species in sera of patients suspected of having TBRF Borrelia infection.
• Recombinant TBRF Borrelia antigens protein sequences listed below were applied as straight lines onto nitrocellulose strips, where they bind. The strips were then be used in the TBRF Borrelia ImmunoBlot Test.
• ImmunoBlotting Immunoblotting is well known to one of ordinary skill in the art.
• TBRF Borrelia ImmunoBlot test patient serum was incubated with TBRF Borrelia ImmunoBlot strips, produced as described above, in each trough of an incubation tray. If specific antibodies to TBRF Borrelia antigens were present in a sample, they were bound to the corresponding antigen bands. After washing away unbound antibodies, the bound TBRF Borrelia specific antibodies were detected with alkaline phosphatase (AP) conjugated goat or rabbit anti-human IgG or IgM antibody. After removing the unbound conjugated antibody, the strips were incubated with BCIP/NBT, an AP chromogenic substrate. A dark purple colored precipitate developed on the antigen-antibody complexes. Bands were visualized and scored for intensity relative to the positive, negative and calibrator (calibration) controls.
• AP alkaline phosphatase
• TBRF ImmunoBlot strips were tested with rabbit anti-TBRF Borrelia serum samples and Borrelia burgdorferi serum samples. Rabbit antibodies to the following Borrelia species were tested: B. hermsii, TBRF Borrelia species, B. coriaceae, B. burgdorferi B31 , B. burgdorferi 297, B. californiensis, B. afzalii, B. garinii, B. spiel manii and B. vaiensiana.
• Table 2b Performance of TBRF Immunoblot on Clinical Samples [0074] To see how a patient’s response immunologically to infection two samples were collected from each of 10 patients (including patients with a history of a tick bite and TBRF PCR positives). Results are presented below in Table 2c
• Sensitivity Based on the data presented above for patients with Lyme-like symptoms, of the 44 patients (total 54 samples) with Lyme-like symptoms, 2 patients had antibodies to B. burgdorferi and TBRF Borrelia ; 29 patients had antibodies to TBRF Borrelia. Four patients with other tick-borne diseases were negative by TBRF
• ImmunoBlot Two sets of serum samples were collected from 10 patients, to see patient’s immune response to infection. We collected two samples at different time points from 10 patients (including patients with a history of a tick bite and/or TBRF PCR positive samples). The second sample was collected 6 weeks to 2 years after the first sample (See Table 2b and Table 2c for detailed results). As shown above, 7 patients (4 IgM (+), 1 IgG (+) and 2 with IgM and IgG) were positive initially. When the second sample was tested all patients were positive, 5 IgM (+), 2 lgG(+) and 3 IgM and IgG (+).
• results show that the TBRF ImmunoBlots can be used in to detect TBRF Borrelia-specific antibodies in patients suspected of TBRF Borreliosis.
• the results can be used by the physician in conjunction with patient history and symptoms. Detailed results are summarized below in Table 3.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Food Science & Technology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Analytical Chemistry (AREA)
• Physics & Mathematics (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Microbiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Organic Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Peptides Or Proteins (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=67843846

Family Applications (1)

Country Status (5)

Families Citing this family (2)

Family Cites Families (6)

• 2018
  • 2018-03-09 US US15/916,717 patent/US10718767B2/en active Active
• 2019
  • 2019-03-07 CA CA3092156A patent/CA3092156A1/en active Pending
  • 2019-03-07 EP EP19763607.9A patent/EP3762725B1/en active Active
  • 2019-03-07 WO PCT/US2019/021113 patent/WO2019173569A1/en not_active Ceased
  • 2019-03-07 JP JP2020546964A patent/JP7366041B2/ja active Active
• 2020
  • 2020-06-30 US US16/916,273 patent/US11353457B2/en active Active

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events